<DOC>
	<DOCNO>NCT02196662</DOCNO>
	<brief_summary>The primary objective study compare rate extent absorption mesalamine-sodium hyaluronate 200 mg-28.75 mg delayed-release capsule ( IBD98-M , Test ) versus Delzicol 400 mg delayed-release capsule ( mesalamine Reference ) , administer single oral dose 2 x 200 mg-28.75 mg delayed-release capsule ( total dose 400 mg-57.50 mg ) 1 x 400 mg delayed-release capsule fast condition .</brief_summary>
	<brief_title>Pharmacokinetics IBD98-M 400mg-57.5/Day Healthy Volunteers</brief_title>
	<detailed_description>Safety population The safety population define subject receive least one dose study medication . Pharmacokinetic Population The pharmacokinetic population include subject complete least 2 period pharmacokinetic profile adequately characterise . Any subject pre-dose concentration mesalamine exclude pharmacokinetic population analyte pre-dose concentration great 5 % Cmax value period subject . Data subject experience emesis sample interval withdrawn per criterion establish section 9.10 may evaluate completion pharmacokinetic analysis . Any subject experience emesis within 2 time median Tmax current study ( base Reference product ) exclude statistical analysis . Data ( concentration pharmacokinetic parameter ) subject exclude due pre dose concentration great 5 % Cmax subject withdraw due adverse event vomit episode present exclude descriptive statistic .</detailed_description>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>1 . Male female , smoker ( 25 cigarette daily ) nonsmoker , 18 year age old , BMI &gt; 18.5 &lt; 30.0 kg/m2 body weight ≥ 50.0 kg male ≥ 45.0 kg female . 2 . Healthy define : absence clinically significant illness surgery within 4 week prior dose . Subjects vomit within 24 hour predose carefully evaluate upcoming illness/disease . Inclusion predosing discretion Qualified Investigator . absence clinically significant history neurological , endocrinal , cardiovascular , pulmonary , hematological , immunologic , psychiatric , gastrointestinal , renal , hepatic , metabolic disease . absence history know pyloric stenosis . absence know gastric duodenal ulcer . absence urinary tract obstruction . 3 . Females childbearing potential sexually active male partner must willing use one follow acceptable contraceptive method throughout study 30 day last study drug administration : intrauterine contraceptive device place least 4 week prior study drug administration condom intravaginally apply spermicide start least 14 day prior study drug administration hormonal contraceptive start least 4 week prior study drug administration must agree use hormonal contraceptive throughout study sterile male partner ( vasectomize since least 6 month ) . 4 . Capable consent . 1 . Any clinically significant abnormality abnormal laboratory test result find medical screening positive test hepatitis B , hepatitis C , HIV find medical screening . 2 . Positive urine drug screen screen . 3 . History allergic reaction mesalamine , salicylate , aminosalicylates , hyaluronic acid , relate drug . 4 . Positive pregnancy test screening . 5 . Any reason , opinion Medical SubInvestigator , would prevent subject participate study . 6 . Clinically significant electrocardiogram ( ECG ) abnormalities vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . 7 . History significant alcohol abuse within one year prior screen regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ 1 Unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) . 8 . History significant drug abuse within one year prior screen use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] , crack ) within 1 year prior screen . 9 . Participation clinical trial involve administration investigational market drug within 30 day ( 90 day biologics ) prior first dose concomitant participation investigational study involve drug administration . 10 . Use medication topical product without significant systemic absorption hormonal contraceptive : prescription medication within 14 day prior first dosing ; overthecounter product include natural health product ( e.g . food supplement herbal supplement ) within 7 day prior first dosing , exception occasional use acetaminophen ( 2 g daily ) ; depot injection implant drug ( hormonal contraceptive ) within 3 month prior first dose . 11 . Donation plasma within 7 day prior dose . Donation loss blood ( exclude volume drawn screen ) 50 mL 499 mL blood within 30 day , 499 mL within 56 day prior first dosing . 12 . Hemoglobin &lt; 128 g/L ( male ) &lt; 115 g/L ( female ) hematocrit &lt; 0.37 L/L ( male ) &lt; 0.32 L/L ( female ) screen . 13 . Breastfeeding subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>